Search Medical Condition
Please enter condition
Please choose location from dropdown

Libramont-Chevigny, Belgium Clinical Trials

A listing of Libramont-Chevigny, Belgium clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Study of Irinotecan Liposome Injection (ONIVYDE ) in Patients With Small Cell Lung Cancer

The study will be conducted in two parts: Part 1: Open-label dose-finding study of irinotecan liposome injection. 30 patients were enrolled. Part 1 Primary Objectives: Describe the safety and tolerability of irinotecan liposome injection monotherapy administered every 2 weeks Determine the optimal irinotecan liposome injection monotherapy dose for Part 2 …

Phase

0.0 miles

Learn More »

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.  

Phase

0.0 miles

Learn More »

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

The main purpose of this study is to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.

Phase

0.0 miles

Learn More »

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Following a lead-in period during which all participants receive a single 3-week cycle of carboplatin/paclitaxel*, participants will be randomly assigned in to one of three treatment arms Pembrolizumab+Olaparib, Pembrolizumab+Placebo for Olaparib Placebo for Pembrolizumab+Placebo for Olaparib At Investigator's discretion and prior to participant randomization, one of the following carboplatin/paclitaxel regimens …

Phase

3.27 miles

Learn More »

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Phase

3.27 miles

Learn More »

ASPIRIN Trial Belgium

The purpose of this study is to determine the effect of 80mg acetylsalicylic acid (given orally once daily for 5 years) on 5 year overall survival (OS) for stage II and III colon cancer patients of 45 years of age and older. Preclinical, epidemiologic and clinical evidence suggest that acetylsalicylic …

Phase

3.27 miles

Learn More »

Avelumab Program Rollover Study

The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.

Phase

3.27 miles

Learn More »

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

This is an international, multicenter, randomized, open-label, active-controlled, event-driven, Phase 3 clinical study comparing the efficacy and safety of elacestrant to the SoC options of fulvestrant or an aromatase inhibitor (AI) in postmenopausal women and in men with advanced or metastatic ER+/HER2- breast cancer, either in subjects with tumors that …

Phase

3.27 miles

Learn More »

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

The study comprises four open-label substudies in patients with advanced urothelial cancer harboring FGFR GA who will be treated by single-agent derazantinib or derazantinib in combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status, or patients whose disease progressed after either first-line treatment or prior treatment with FGFR inhibitors.

Phase

3.27 miles

Learn More »

A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer

Post-menopausal women with histologically or cytologically confirmed metastatic or loco-regionally recurrent ER-positive HER2-negative breast cancer before randomization and fulfilling all of the inclusion criteria and none of the exclusion criteria will be included. After the screening visit and confirmation of eligibility, patients will be randomly assigned in a 1:1:1:1 ratio …

Phase

3.27 miles

Learn More »